Reslizumab (Cinqair®)

Covered: Cinqair (reslizumab) is covered as add‑on maintenance therapy for adults (≥18 years) with severe eosinophilic asthma and is not covered for patients <18 or those who do not meet the policy’s eosinophil, prior‑therapy, or disease severity/uncontrolled criteria. Key requirements: blood eosinophils ≥400 cells/µL within 4 weeks (or within 4 weeks prior to treatment with another mAb that may lower eosinophils), ≥3 months of prior inhaled corticosteroid plus an additional controller, documented uncontrolled asthma by ≥1 specified criterion (≥2 systemic‑steroid exacerbations in the past year, ≥1 hospitalization/ER, FEV1 <80% predicted, FEV1/FVC <0.80, or worsening on oral steroid taper), prescription by/consult with an allergist/immunologist/pulmonologist, initial approval for 6 months (renewal 12 months) with reauthorization only after ≥6 months of therapy and documented clinical response while remaining on an ICS or ICS‑containing inhaler; recommended dosing 3 mg/kg IV every 4 weeks.